Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis

被引：0
|
作者：
Quan Rao
Min Li
Wei Xu
Kai Pang
XiaoBo Guo
Dong Wang
Jun Liu
Wei Guo
ZhongTao Zhang
机构：
[1] Capital Medical University,Department of General Surgery, Beijing Friendship Hospital
[2] Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases,Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital
[3] Capital Medical University,Department of Vascular Surgery, Beijing Friendship Hospital
[4] Capital Medical University,undefined
来源：
Hepatology International | 2020年 / 14卷
关键词：
PD-1; PD-L1; Monoclonal antibody; Nivolumab; Pembrolizumab; Anti-VEGF agent; Objective response rate; Disease control rate; Overall survival; Progression-free survival; Adverse event; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：765 / 775
页数：10
相关论文
共 50 条
  • [41] Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis
    Nishuima, Tomohiro F.
    Shachar, Shlomit S.
    Muss, Hyman B.
    Tamura, Kazuo
    [J]. ONCOLOGIST, 2019, 24 (07): : E565 - E573
  • [42] Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis
    Zhou, Xueyin
    Cao, Jiasheng
    Topatana, Win
    Xie, Tianao
    Chen, Tianen
    Hu, Jiahao
    Li, Shijie
    Juengpanic, Sarun
    Lu, Ziyi
    Zhang, Bin
    Wang, Kaitai
    Feng, Xu
    Shen, Jiliang
    Chen, Mingyu
    [J]. IMMUNOTHERAPY, 2023, 15 (05) : 353 - 365
  • [43] EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS USED IN THE TREATMENT OF PATIENTS WITH ADVANCED AND METASTATIC MELANOMA - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Oguzhan, G.
    Caliskan, Z.
    Kockaya, G.
    Kurnaz, M.
    Calli, C.
    Erturk, S. M.
    [J]. VALUE IN HEALTH, 2020, 23 : S50 - S50
  • [44] EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS USED IN THE TREATMENT OF PATIENTS WITH ADVANCED AND METASTATIC MELANOMA - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Verma, J.
    Verma, D.
    Maria, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S50 - S50
  • [45] Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis
    Oh, SuA
    Kim, Eunyoung
    Lee, Heeyoung
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [46] PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
    Khan, Muhammad
    Du, Kunpeng
    Ai, Meiling
    Wang, Baiyao
    Lin, Jie
    Ren, Anbang
    Chen, Chengcong
    Huang, Zhong
    Qiu, Wenze
    Yuan, Yawei
    Tian, Yunhong
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma
    Feng, Zhichao
    Rong, Pengfei
    Wang, Wei
    [J]. GUT, 2020, 69 (10) : 1904 - 1906
  • [48] Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis
    Yin, Gaofei
    Guo, Wei
    Duan, Hanyuan
    Huang, Zhigang
    [J]. CLINICAL OTOLARYNGOLOGY, 2021, 46 (05) : 1013 - 1020
  • [49] Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
    Huang, Shibo
    Huang, Yanping
    Li, Chunyan
    Liang, Yiwen
    Huang, Miaoyan
    Luo, Raoshan
    Liang, Weiming
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [50] Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review
    Han, Deting
    Dong, Jianyong
    Li, Honglin
    Ma, Tao
    Yu, Wenjun
    Song, Lucheng
    [J]. MEDICINE, 2020, 99 (05) : E18701
12345